Antengene Corporation Limited
德琪醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 6996)

VOLUNTARY ANNOUNCEMENT

NMPA GRANTED MARKETING APPROVAL FOR SELINEXOR (ATG-010) IN CHINA

This announcement is made by Antengene Corporation Limited (the "**Company**" or "**Antengene**", together with its subsidiaries, the "**Group**" or "**we**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board (the "**Board**") of directors of the Company is pleased to announce that selinexor (ATG-010) (brand name: XPOVIO®，希維奧®), a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, has been granted conditional approval for marketing issued by the National Medical Products Administration (the "**NMPA**"), applicable in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received prior therapies and whose disease is refractory to at least a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

The conditional approval of XPOVIO® was based on results from the global Phase 2 STORM trial, as well as the Phase 2 MARCH trial in China evaluating the efficacy and safety of selinexor plus dexamethasone in 82 patients with relapsed/refractory multiple myeloma (RRMM). Results of the STORM trial showed that the overall response rate (ORR), the primary endpoint, as assessed by an Independent Review Committee (IRC) based on the International Myeloma Working Group (IMWG) Uniform Response Criteria, was 25.3% for the prespecified subgroup of 83 patients whose disease was refractory to bortezomib, carfilzomib, lenalidomide, pomalidomide, and daratumumab. The MARCH trial showed that the efficacy and safety in Chinese patients whose diseases were refractory to both lenalidomide and bortezomib, as well as the last line of therapy (with some also refractory to anti-CD38 monoclonal antibody) were generally consistent with that seen in the global study. The overall response rate, the primary endpoint, was 29.3% by IRC for all treated patients in the MARCH trial, and 25% for patients refractory to at least a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

The ongoing, randomized Phase 3 BENCH trial evaluating selinexor in combination with bortezomib and low-dose dexamethasone will serve as the confirmatory trial.

About the SINE Compounds

SINE (Selective Inhibitor of Nuclear Export) compounds are inhibitors of the major nuclear export protein Exportin 1 (XPO1). Currently, there are three oral SINE compounds, ATG-010 (Selinexor), ATG-016 (Eltanexor), and ATG-527 (Verdinexor), under clinical development. Antengene has an exclusive license from Karyopharm Therapeutics Inc. ("**Karyopharm**") to these compounds in certain Asia-Pacific markets.

ATG-010/Selinexor/XPOVIO®

Selinexor is the first and only oral XPO1 inhibitor approved by the U.S. Food and Drug Administration (FDA). By blocking the nuclear export protein XPO1, selinexor can promote the intranuclear accumulation and activation of tumor suppressor proteins and growth regulating proteins, and down-regulate the levels of multiple oncogenic proteins. This induces apoptosis without affecting normal cells. Due to its novel mechanism of action, selinexor is being evaluated for use in multiple combination regimens to improve treatment efficacy.

Selinexor is approved by the US FDA for the treatment of relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory diffuse large B-cell lymphoma.

Antengene secured approval of selinexor in South Korea through a priority review process prior to the current approval in mainland China. Antengene is conducting 10 studies with selinexor in mainland China (3 in collaboration with Karyopharm) for relapsed/refractory hematological malignancies and advanced solid tumors.

About Antengene

Antengene Corporation Limited (SEHK: 6996.HK) is a leading clinical-stage R&D- driven global biopharmaceutical company focused on innovative first-in-class/best-in-class therapeutic medicines for oncology and other life-threatening diseases. Driven by its vision of "Treating Patients Beyond Borders", Antengene aims to provide the most advanced anti-cancer drugs to patients in the Asia Pacific Region and around the world. Since initiating operations in 2017, Antengene has obtained 20 investigational new drug (IND) approvals in the US and in Asia, submitted 6 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for selinexor/ATG-010 in mainland China and South Korea already approved through a priority review process. Leveraging partnerships as well as in-house drug discovery, Antengene has built a broad and expanding pipeline of 15 clinical and pre-clinical assets. The Company has global rights on 10 programs and Asia Pacific rights, including the Greater China region, on 5 programs.

Forward-looking statements

The forward-looking statements made in this announcement only to the events or information as of the date on which the statements are made in this announcement. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this announcement completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this announcement, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this announcement. Any of these intentions may alter in light of future development.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to ultimately market ATG-010 (selinexor) successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Antengene Corporation Limited
Dr. Jay Mei
Chairman

Hong Kong, December 17, 2021

As at the date of this announcement, the board of directors of the Company comprises Dr. Jay Mei, Mr. John F. Chin, Mr. Donald A. Lung and Dr. Kevin P. Lynch as executive directors; Mr. Yilun Liu and Dr. Kan Chen as non-executive directors; and Mr. Mark J. Alles, Ms. Jing Qian and Mr. Sheng Tang as independent non-executive directors.